GlycA, a novel inflammatory marker, is associated with subclinical coronary disease

Martin Tibuakuu; Oluwaseun E. Fashanu; Di Zhao; James D. Otvos; Todd T. Brown; Sabina A. Haberlen; Eliseo Guallar; Matthew J. Budoff; Frank J. Palella; Jeremy J. Martinson; Akintunde O. Akinkuolie; Samia Mora; Wendy S. Post; Erin D. Michos

doi:10.1097/QAD.0000000000002079

GlycA, a novel inflammatory marker, is associated with subclinical coronary disease

Martin Tibuakuu^*, Oluwaseun E. Fashanu, Di Zhao, James D. Otvos, Todd T. Brown, Sabina A. Haberlen, Eliseo Guallar, Matthew J. Budoff, Frank J. Palella, Jeremy J. Martinson, Akintunde O. Akinkuolie, Samia Mora, Wendy S. Post, Erin D. Michos

^*Corresponding author for this work

Medicine, Infectious Diseases Division

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

GlycA, a novel NMR biomarker of inflammation, has been associated with incident cardiovascular disease (CVD) in the general population, but its association with CVD among HIV-infected individuals is unknown. We examined the associations between GlycA and subclinical coronary plaque among HIV-infected and HIV-uninfected men participating in Multicenter AIDS Cohort Study (MACS).Design:Cross-sectional analysis of 935 men with plasma measurement of GlycA and noncontrast cardiac computed tomography (CT) and/or coronary CT angiography.Methods:We used multivariable Poisson and linear regression to assess associations of GlycA with prevalent coronary atherosclerosis and plaque extent, respectively.Results:Mean±SD age was 54±7 years; 31% were black; 63% HIV-infected. GlycA levels were higher in HIV-infected compared with HIV-uninfected men (397±68 vs. 380±60μmol/l, P=0.0001) and higher for men with detectable viral load vs. undetectable (413±79 vs. 393±65μmol/l, P=0.004). After adjusting for HIV serostatus, demographic and CVD risk factors, every 1SD increment in GlycA level was associated with a higher prevalence of coronary artery calcium (CAC >0) [prevalence ratio 1.09 (95% CI 1.03-1.15)] and coronary stenosis at least 50% [1.20 (1.02-1.41)]. These associations were not significantly altered after adjusting for traditional inflammatory biomarkers or differ by HIV serostatus. Among men with plaque, GlycA was positively associated with the extent of CAC and total plaque.Conclusion:HIV infection was associated with higher GlycA levels. In both HIV-infected and HIV-uninfected individuals, GlycA was significantly associated with several measures of subclinical coronary atherosclerosis, independent of other CVD risk factors and inflammatory biomarkers. These findings suggest the potential role of GlycA in CVD risk stratification among HIV patients.

Original language	English (US)
Pages (from-to)	547-557
Number of pages	11
Journal	AIDS
Volume	33
Issue number	3
DOIs	https://doi.org/10.1097/QAD.0000000000002079
State	Published - Mar 1 2019

Funding

Funding sources: This study is funded by the National Heart, Lung and Blood Institute (NHLBI) grant R01 HL095129 to Dr W.S.P. The MACS is funded by the National Institute of Allergy and Infectious Diseases (NIAID), with additional supplemental funding from the National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA), the National Institute of Mental Health (NIMH), and the NHLBI as follows: UO1-AI-35042, UL1-RR025005, UM1-AI-35043, UO1-AI-35039, UO1-AI-35040, UO1-AI-35041. E.D.M. and D.Z. are supported by the Blumenthal Scholars Program in Preventive Cardiology. T.T.B. is supported in part by the National Institute for Allergy and Infectious Diseases (K24 AI120834). S.M. is supported by the NHLBI (R01HL134811 and K24 HL136852), and the National Institute of Diabetes and Digestive and Kidney Diseases (DK112940). Role of the Sponsor: This work was funded by grants from the NIH, but the funding source had no input in writing or design of manuscript.

Keywords

GlycA
HIV infection
cardiac computed tomography
coronary artery calcium
coronary atherosclerosis
inflammation

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/QAD.0000000000002079

Cite this

@article{5c3052477ee34ae0b2ff7c5277b54621,

title = "GlycA, a novel inflammatory marker, is associated with subclinical coronary disease",

abstract = "GlycA, a novel NMR biomarker of inflammation, has been associated with incident cardiovascular disease (CVD) in the general population, but its association with CVD among HIV-infected individuals is unknown. We examined the associations between GlycA and subclinical coronary plaque among HIV-infected and HIV-uninfected men participating in Multicenter AIDS Cohort Study (MACS).Design:Cross-sectional analysis of 935 men with plasma measurement of GlycA and noncontrast cardiac computed tomography (CT) and/or coronary CT angiography.Methods:We used multivariable Poisson and linear regression to assess associations of GlycA with prevalent coronary atherosclerosis and plaque extent, respectively.Results:Mean±SD age was 54±7 years; 31% were black; 63% HIV-infected. GlycA levels were higher in HIV-infected compared with HIV-uninfected men (397±68 vs. 380±60μmol/l, P=0.0001) and higher for men with detectable viral load vs. undetectable (413±79 vs. 393±65μmol/l, P=0.004). After adjusting for HIV serostatus, demographic and CVD risk factors, every 1SD increment in GlycA level was associated with a higher prevalence of coronary artery calcium (CAC >0) [prevalence ratio 1.09 (95% CI 1.03-1.15)] and coronary stenosis at least 50% [1.20 (1.02-1.41)]. These associations were not significantly altered after adjusting for traditional inflammatory biomarkers or differ by HIV serostatus. Among men with plaque, GlycA was positively associated with the extent of CAC and total plaque.Conclusion:HIV infection was associated with higher GlycA levels. In both HIV-infected and HIV-uninfected individuals, GlycA was significantly associated with several measures of subclinical coronary atherosclerosis, independent of other CVD risk factors and inflammatory biomarkers. These findings suggest the potential role of GlycA in CVD risk stratification among HIV patients.",

keywords = "GlycA, HIV infection, cardiac computed tomography, coronary artery calcium, coronary atherosclerosis, inflammation",

author = "Martin Tibuakuu and Fashanu, {Oluwaseun E.} and Di Zhao and Otvos, {James D.} and Brown, {Todd T.} and Haberlen, {Sabina A.} and Eliseo Guallar and Budoff, {Matthew J.} and Palella, {Frank J.} and Martinson, {Jeremy J.} and Akinkuolie, {Akintunde O.} and Samia Mora and Post, {Wendy S.} and Michos, {Erin D.}",

year = "2019",

month = mar,

day = "1",

doi = "10.1097/QAD.0000000000002079",

language = "English (US)",

volume = "33",

pages = "547--557",

journal = "AIDS",

issn = "0269-9370",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - GlycA, a novel inflammatory marker, is associated with subclinical coronary disease

AU - Tibuakuu, Martin

AU - Fashanu, Oluwaseun E.

AU - Zhao, Di

AU - Otvos, James D.

AU - Brown, Todd T.

AU - Haberlen, Sabina A.

AU - Guallar, Eliseo

AU - Budoff, Matthew J.

AU - Palella, Frank J.

AU - Martinson, Jeremy J.

AU - Akinkuolie, Akintunde O.

AU - Mora, Samia

AU - Post, Wendy S.

AU - Michos, Erin D.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - GlycA, a novel NMR biomarker of inflammation, has been associated with incident cardiovascular disease (CVD) in the general population, but its association with CVD among HIV-infected individuals is unknown. We examined the associations between GlycA and subclinical coronary plaque among HIV-infected and HIV-uninfected men participating in Multicenter AIDS Cohort Study (MACS).Design:Cross-sectional analysis of 935 men with plasma measurement of GlycA and noncontrast cardiac computed tomography (CT) and/or coronary CT angiography.Methods:We used multivariable Poisson and linear regression to assess associations of GlycA with prevalent coronary atherosclerosis and plaque extent, respectively.Results:Mean±SD age was 54±7 years; 31% were black; 63% HIV-infected. GlycA levels were higher in HIV-infected compared with HIV-uninfected men (397±68 vs. 380±60μmol/l, P=0.0001) and higher for men with detectable viral load vs. undetectable (413±79 vs. 393±65μmol/l, P=0.004). After adjusting for HIV serostatus, demographic and CVD risk factors, every 1SD increment in GlycA level was associated with a higher prevalence of coronary artery calcium (CAC >0) [prevalence ratio 1.09 (95% CI 1.03-1.15)] and coronary stenosis at least 50% [1.20 (1.02-1.41)]. These associations were not significantly altered after adjusting for traditional inflammatory biomarkers or differ by HIV serostatus. Among men with plaque, GlycA was positively associated with the extent of CAC and total plaque.Conclusion:HIV infection was associated with higher GlycA levels. In both HIV-infected and HIV-uninfected individuals, GlycA was significantly associated with several measures of subclinical coronary atherosclerosis, independent of other CVD risk factors and inflammatory biomarkers. These findings suggest the potential role of GlycA in CVD risk stratification among HIV patients.

AB - GlycA, a novel NMR biomarker of inflammation, has been associated with incident cardiovascular disease (CVD) in the general population, but its association with CVD among HIV-infected individuals is unknown. We examined the associations between GlycA and subclinical coronary plaque among HIV-infected and HIV-uninfected men participating in Multicenter AIDS Cohort Study (MACS).Design:Cross-sectional analysis of 935 men with plasma measurement of GlycA and noncontrast cardiac computed tomography (CT) and/or coronary CT angiography.Methods:We used multivariable Poisson and linear regression to assess associations of GlycA with prevalent coronary atherosclerosis and plaque extent, respectively.Results:Mean±SD age was 54±7 years; 31% were black; 63% HIV-infected. GlycA levels were higher in HIV-infected compared with HIV-uninfected men (397±68 vs. 380±60μmol/l, P=0.0001) and higher for men with detectable viral load vs. undetectable (413±79 vs. 393±65μmol/l, P=0.004). After adjusting for HIV serostatus, demographic and CVD risk factors, every 1SD increment in GlycA level was associated with a higher prevalence of coronary artery calcium (CAC >0) [prevalence ratio 1.09 (95% CI 1.03-1.15)] and coronary stenosis at least 50% [1.20 (1.02-1.41)]. These associations were not significantly altered after adjusting for traditional inflammatory biomarkers or differ by HIV serostatus. Among men with plaque, GlycA was positively associated with the extent of CAC and total plaque.Conclusion:HIV infection was associated with higher GlycA levels. In both HIV-infected and HIV-uninfected individuals, GlycA was significantly associated with several measures of subclinical coronary atherosclerosis, independent of other CVD risk factors and inflammatory biomarkers. These findings suggest the potential role of GlycA in CVD risk stratification among HIV patients.

KW - GlycA

KW - HIV infection

KW - cardiac computed tomography

KW - coronary artery calcium

KW - coronary atherosclerosis

KW - inflammation

UR - http://www.scopus.com/inward/record.url?scp=85060885027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060885027&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000002079

DO - 10.1097/QAD.0000000000002079

M3 - Article

C2 - 30475263

AN - SCOPUS:85060885027

SN - 0269-9370

VL - 33

SP - 547

EP - 557

JO - AIDS

JF - AIDS

IS - 3

ER -

GlycA, a novel inflammatory marker, is associated with subclinical coronary disease

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this